Alzheimer’s research has stalled for decades despite enormous pharma investment, primarily because the dominant amyloid hypothesis may be incomplete or wrong.
Key Takeaways
The amyloid cascade hypothesis (targeting Abeta 42 peptide fragments) has monopolized research funding and clinical trial design for 30+ years.
Pharma has burned billions on amyloid-targeting drug programs that showed preclinical activity but failed in humans.
Recent approvals of Lecanemab and Donanemab show modest progression-slowing benefit, suggesting amyloid-beta has some causal role but was not the full answer.
The field increasingly views “Alzheimer’s” as a heterogeneous group of diseases rather than a single condition with a single mechanism.
Grant structures historically rewarded researchers who stayed within the amyloid consensus, concentrating risk on one model.
Hacker News Comment Review
Commenters broadly agree the core failure was institutional lock-in, not just scientific error: grant funding flowed to amyloid researchers, crowding out competing hypotheses for two-plus decades.
There is real disagreement on whether amyloid is causal or symptomatic. Some cite a 2010-era finding that amyloid aggregates lacked mechanistic causation; others point to Lecanemab and Donanemab trial data as strong evidence amyloid-beta is at least partially causal, but that early drugs targeted the wrong aggregated form.
Several commenters argue the deeper problem is framing Alzheimer’s as a discrete disease rather than a downstream symptom of senescence, which faces its own ideological and funding headwinds in medicine.
Notable Comments
@robwwilliams: Recommends Karl Herrup’s How Not to Study a Disease (MIT Press, 2021) as the authoritative critique of monomaniacal amyloid focus and its grant-reward dynamics.
@hn_throwaway_99: Flags early-stage Harvard research on low brain lithium as a potential Alzheimer’s mechanism, with concern it will be underfunded because lithium is cheap and unpatentable.
@chermi: Notes that papers showing no real mechanistic link between amyloid aggregates and disease were already circulating in 2010, sixteen years before this discussion.
